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The GALA Trial e A Summary of the FindingsThe role for carotid endarterectomy (CEA) in reducing the
subsequent stroke risk following an ipsilateral transient
ischaemic attack (TIA) or non-disabling ischaemic stroke in
patients with a significant internal carotid artery (ICA)
stenosis is well established.1 A lesser benefit occurs after
surgery for asymptomatic carotid stenoses.2 Nevertheless
CEA is associated with a 30-day stroke risk of 5e7%3 and
strategies that reduce this risk would be important.
The GALA (general versus local anaesthesia) Trial was
conceived following publication of data from non-rando-
mised studies suggesting that local or regional anaesthesia
(LA) was associated with a 50% reduction in stroke and
death rates for CEA compared to general anaesthesia (GA).4
A subsequent Cochrane Review of both non-randomised and
randomised studies reached similar conclusions.5 The
potential advantages of LA CEA include accurate assess-
ment of neurological function (awake testing) following
carotid clamping and clear identification of patients with
cerebral hypoperfusion requiring a carotid shunt and pres-
ervation of cerebral autoregulation.6 Thus fewer shunts are
used under LA, reducing the risk of air or particulate
embolism to the brain and of arterial injury that might
promote post-operative carotid thrombosis. Further, GA
could result in more cardiorespiratory risks in elderly
patients. Although both anaesthetic techniques have been
used with varying enthusiasm since the 1950s there has
been no consensus as to which is safer. Thus, the GALA Trial
was designed to determine whether the type of anaesthesia
influenced peri-operative morbidity and mortality (partic-
ularly from stroke), quality of life in the short term, and
stroke and myocardial infarction-free survival to one year.
GALA is the largest randomised surgical/anaesthetic trial
ever performed and included 3526 patients recruited by 95
centres in 24 countries. Although power calculations sug-
gested that up to 5000 patients might be required to
confirm a one third reduction in the primary outcome
events of stroke (including retinal infarction), myocardial
infarction and death (from 7.5% to 5%) within 30 days of
surgery this was a more conservative effect than that sug-
gested by the previous meta-analysis5 and recruitment was
terminated after a one-year extension to the proposed1078-5884/$34 ª 2008 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2008.09.001recruitment period. Primary outcome data is available for
99.9% of patients.
Analysis of the results has shown that primary outcome
events were observed (randomisation e 30 days post-
surgery) in 84/1752 (4.8%) GA and 80/1771 (4.5%) LA
patients. This difference is not statistically significant with
3 events prevented/1000 LA patients (95% confidence
interval 11, þ17); risk ratio 0.94 (95% CI 0.70, 1.27).
Similarly, when primary outcome events are considered
individually no significant differences were identified:
stroke 70 (4.0%) GA patients versus 66 (3.7%) LA patients (3
strokes prevented/1000 LA patients (95% CI 10 to þ16)),
risk ratio 0.93 (95% CI 0.67e1.30); death 26 (1.5%) GA
patients versus 19 (1.1%) LA patients (4 events prevented
per 1000 (95% CI 3 to þ12); risk ratio 0.72 (95% CI 0.40e
1.30)); fatal and non-fatal myocardial infarctions LA 9
(0.5%) versus GA 4 (0.2%) patients (3 more events/1000 LA
patients (95% CI 2 to þ8)). Even if recruitment had
continued until the target of 5000 patients had been
reached the findings almost certainly would have been the
same.
Similarly there were no differences between LA and GA
for patients aged > or <75 years or for those considered at
higher risk from surgery using a previously defined algo-
rithm.7 A third pre-defined sub-group for analysis were
patients with a contralateral carotid occlusion. In 310
patients with contralateral carotid occlusion there were 23
primary outcome events (15/150 (10%) GA versus 8/160 (5%)
LA, P for interaction 0.098). Further, neurological events
were more likely to occur contralateral to the operated
artery (i.e. on the same side as the occlusion) in the GA
group (54% versus 29%). Thus LA may offer an advantage for
patients with a contralateral occlusion although this
requires further confirmation.
Although GALA was not powered detect a difference
between LA and GA for peri-operative death alone, when
our data is combined with that from randomised trials in
the Cochrane Review the impact of LA ranges from a 64%
reduction to a 7% increase for this end-point. Further one-
year survival data for GALA patients suggests fewer subse-
quent events (stroke, death, MI) in LA patients (log rankd by Elsevier Ltd. All rights reserved.
506 M.J. Goughtest PZ 0.094). Additional follow-up is required to estab-
lish the validity of this trend.
Although the findings might question the validity of the
original hypothesis, there are a number of reasons why they
are not surprising. In particular the overall results for CEA
were significantly better than those reported in all previous
trials which included independent peer review for outcome
assessment. With fewer primary outcome events it is much
more difficult to show a difference between the two
‘‘treatments’’. It also seems likely that the reflex rise in
systolic blood pressure following application of the carotid
clamps with LA (the mechanism by which LA facilitates
autoregulation) became recognised by anaesthetists who
mimicked this pharmacologically during GA surgery. Thus,
blood pressure was manipulated ‘‘up’’ in 43% of GA patients
compared to 17% of LA patients.
Finally carotid patches were used in fewer patients in
the LA group (42% versus 50%) which, given the evidence
from a previous Cochrane Review8 might have had some
influence on outcomes in this group.
A potential criticism of the Trial is that these differences
in blood pressure manipulation and patching rates would
have been avoided by a more prescriptive study protocol.
This might also be considered the case for other variables
(indications for surgery, diagnostic methods, anaesthetic
drugs and techniques, heparin dose, antiplatelet therapy,
endarterectomy technique). Such a rigid approach would
almost certainly have had a detrimental effect upon
recruitment in an international multicentre study. Equally
a more pragmatic approach should improve the general-
isability of the results.
A further potential criticism of the trial design is that
clinicians might not have randomised higher risk patients
who were considered better suited to one or the other
types of anaesthetic. A prospective log of non-randomised
patients in each centre might have answered this question
but was not considered practical.
Potentially important secondary end-points of time
spent in high dependency or intensive care and total
hospital stay were also similar in both arms of the trial.
That there was no difference between the groups might
reflect adherence to pre-existing care pathways rather than
adopting an individual management plan based on each
patient’s specific requirements. Finally there was no
difference in post-operative quality of life data collected
4e6 weeks after surgery. It is conceivable that any advan-
tage to LA would only have been identified if this infor-
mation had been collected earlier.
In summary the GALA Trial has clearly shown that
outcomes for carotid endarterectomy have improved since
publication of the ECST and NASCET trials with a reduction
in primary outcome events of more than a third. The Trialalso shows that both methods of anaesthesia are safe and
that the anaesthetist and surgeon, in consultation with the
patient, should probably determine the method of anaes-
thesia. However, for patients with a contralateral carotid
occlusion it is tempting to suggest that LA might offer some
benefit, presumably related to its effect on preserving
autoregulation and therefore blood flow to the contralat-
eral hemisphere. Similarly, the trends suggesting fewer
peri-operative deaths and improved one-year survival
following LA surgery require further analysis.References
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